ImClone expected to get Erbitux approved by FDA this time

02/11/2004 | NYTimes.com

The drug that was rejected by the FDA, sparking a Wall Street scandal, is back before the agency for approval, with ImClone Systems making a new effort to get the agency's OK for its cancer drug. Analysts believe better clinical trial data are available this time, and the FDA is expected to give its approval before the deadline for a decision expires this week.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC